- Coordinator
- Zafiro Business Solutions Korlatolt Felelossegu Tarsasag, Hungary
- Runs
- 1 June 2023 to 31 May 2027
- Status
- Running
- EU funding
- €7.6m
- Total cost
- €7.6m
- Partners
- 8 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101080692
What the project is doing
In the project's own words, from its summary on CORDIS.
Researchers worldwide have been working to develop a universal flu vaccine, but no breakthrough has yet been achieved. FLUniversal is not ""another costly universal flu project"". It is an opportunity to create a genuine universal flu vaccine that will set the standard for rapid, efficient vaccine development, and generate know-how and tools to develop next-generation vaccines. We plan to exploit our increased understanding of molecular mechanisms of influenza infection and immunity to develop a vaccine effective against all flu virus strains.
Our innovation uses genetically modified flu strains administered intranasally in a prime-boost regimen. This approach rapidly induces interferon and broadly cross-neutralising antibodies in the nasal passages and a systemic immune response directed to the conserved HA stalk. Proof of concept for universal protection was demonstrated in the ferret
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Zafiro Business Solutions Korlatolt Felelossegu Tarsasag | Budapest | Hungary | Coordinator |
| Vivaldi Biosciences AG | Wien | Austria | Participant |
| Meditox S.r.o | Konarovice | Czechia | Participant |
| Statens Serum Institut | Kobenhavn S | Denmark | Participant |
| Vismederi SRL | Colle Di Val D'Elsa Si | Italy | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Stichting Centre for Human Drug Research | Leiden | Netherlands | Participant |
| Medicines and Healthcare Products Regulatory Agency | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI